T. Rowe Price Associates
VINC

T. Rowe Price Associates’s Vincerx Pharma, Inc. Common Stock VINC Stock Holding History

T. Rowe Price Associates’s Portfolio VINC Stock Details VINC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,500
Closed -$152K – 3054
2024
Q1 		$152K Sell
1,500
-500
-25% -$31.6K ﹤0.01% 2693
2023
Q4 		$48K Hold
2,000
– – ﹤0.01% 2812
2023
Q3 		$42K Buy
+2,000
New +$38.8K ﹤0.01% 2795

Other funds holding VINC

PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SRC
Sage Rhino Capital Menlo Park, California $617M AUM 28.74% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates's VINC Position: Q2 2024 in Review

T. Rowe Price Associates sold out of Vincerx Pharma, Inc. Common Stock (VINC) in Q2 2024, closing a stake of 1,500 shares — an estimated $152K sold.

T. Rowe Price Associates first reported a position in VINC in Q3 2023 and held it in 3 quarters. The position peaked at $152K in Q1 2024. 27 funds tracked by Wall St. Rank hold VINC as of Q2 2024.

  • T. Rowe Price Associates reported no remaining Vincerx Pharma, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 1,500 Vincerx Pharma, Inc. Common Stock shares in Q2 2024, an estimated $152K.
  • T. Rowe Price Associates first reported a position in Vincerx Pharma, Inc. Common Stock in Q3 2023 and held it in 3 quarters.
  • T. Rowe Price Associates's Vincerx Pharma, Inc. Common Stock position peaked at $152K in Q1 2024.
  • 27 funds tracked by Wall St. Rank held Vincerx Pharma, Inc. Common Stock as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.